News for hackers. Stuff that matters.
Re:Jump in cancer diagnoses at 65 implies patients wait for ... by rootusrootus on Wednesday March 31, 2021 @08:07PM (#26654971)
There is some merit to that argument, because we have artificially constrained the supply of doctors in order to sustain their high salaries. Perverse is a polite word for the situation.
Re:Jump in cancer diagnoses at 65 implies patients wait for ... by vkou on Wednesday March 31, 2021 @08:15PM (#26655057)
There is no country in the world that does not have an 'artificially constrained supply of doctors.'

Yet most of those countries have cheaper/better/cheaper and better health outcomes.

'The supply of doctors is constrained' is largely a red herring.

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by bumby on Wednesday March 31, 2021 @08:37PM (#26655269)
Not disagreeing necessarily, but I’m not sure the 1:1 comparison works with “most of those countries”. For example, the US is burdened by a disproportionate amount of R&D which helps to lower costs in other countries. It’s a complex problem and overly simplified comparisons don’t often offer a real fix
Re:Jump in cancer diagnoses at 65 implies patients wait for ... by vkou on Wednesday March 31, 2021 @08:51PM (#26655385)
> For example, the US is burdened by a disproportionate amount of R&D which helps to lower costs in other countries.

This doesn't explain the disproportionate costs of decades-old medications and procedures still using decades-old methods.

You can maybe justify high drug costs based on that, but drug costs are a small fraction of overall medical costs.

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by bumby on Wednesday March 31, 2021 @09:06PM (#26655488)
To an extent, it does. Particularly when other countries have cost control regulations, the companies are incentivized to make up those R&D costs elsewhere. Today’s drug profits are funding tomorrow’s novel medicine.

Note in not saying this is ethically fair or optimal, just that it’s a consequence of the particular system

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by vkou on Wednesday March 31, 2021 @09:53PM (#26655779)
Again, drugs are a only a small part of overall health costs. They only make up 14% of healthcare spending[1] in the US. For contrast, they make up ~15% of healthcare spending in Canada, and ~16% of healthcare spending in the UK.

Your theory does not explain why the other 86% is so bloated.

[1] https://www.drugcostfacts.org/us-healthcare-spending

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by bumby on Wednesday March 31, 2021 @10:01PM (#26655840)
All my comments were deliberately couched to specifically not pretend there is a simple answer to healthcare cost bloat in the US. It is merely a testament to a single factor that increases costs while also inhibiting naive comparisons. The US healthcare system is awfully complex to even scratch the surface about causal factors in a forum post.

Beyond that, you may be conflating prescription costs with drug research, which is not the same. The fact that prescription costs take up roughly the same percentage of total healthcare costs seems to support my point. An equal percentage of a bigger pie would indicate they are inflated.

My personal stance is that the US optimized for access and quality at the expense of cost. As the saying goes, you can only have two. R&D spending is a large part of this. The US contributes over 40% of the worlds medical R&D, effectively subsidizing other nations. It’s not a bad thing and it doesn’t explain away all healthcare costs but it does create systemic ramifications. It’s been awhile since I’ve viewed the numbers, but the US had the highest health access and quality scores for a country of comparable size. Off the top of my head, I think the next closest was Russia. Again, the point being simple comparisons are harder than one may think when dealing with complex systems.

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by vkou on Wednesday March 31, 2021 @11:35PM (#26656394)
The only countries of comparable size to the United States are in the developing world. That's a horrible bar for the richest country in the world to be trying to meet. If anything, it has the unique advantage of having unprecedented economies of scale among developed nations.

I keep harping on drug prices, because you keep mentioning R&D. R&D is not the reason for why non-drug healthcare is so expensive. There is no mechanism by which high R&D costs lead to high specialist/GP/nursing/administration costs. There's no way for, say, Pfizer to siphon money from any of that into R&D. R&D is not the reason for why these costs are so high.

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by bumby on Thursday April 01, 2021 @10:38AM (#26661011)
I’m only reiterating this because your responses make me think I’m not stating my central claim clearly enough: there is not “a reason” healthcare in the US is expensive. There are multiple, sometimes covariant reasons. Only one of those is drug prices. And if you don’t think pharmaceutical companies impact those other healthcare costs, you may not have a sound understanding of the healthcare system.

Related to your comment about the difficulties in comparison, you underscored my other point. People flippantly say “but look at country X’s costs” without understanding the nuances that make such comparisons worthless.

Re:Jump in cancer diagnoses at 65 implies patients wait for ... by mbroncano on Wednesday March 31, 2021 @08:41PM (#26655301)
The point in my opinion is lost, because in those countries you might be referring to, the doctors earn a fraction of what they do in the US.
Re:Jump in cancer diagnoses at 65 implies patients wait for ... by vkou on Wednesday March 31, 2021 @08:53PM (#26655402)
Well, if it comes to making a choice between better health outcomes, weighed against doctors only making six figures a year (and medical schools only charging five figures per year), I think the choice for most of us would be pretty simple.